ABSTRACT: Fifteen yearling fallow bucks were randomly assigned by BW to one of three treatment groups: control (C; n = 5), melengestrol acetate (MGA; n = 5), and zeranol (Z; n = 5), to evaluate effects on testicular development, aggressive behavior, antler growth, sexual activity, ADG, and BW. Zeranol-treated bucks received zeranol ear implants (36 mg) at 90-d intervals, and MGA-treated bucks received MGA in the ration (100 gؒanimal
Introduction
Fallow deer (Dama dama) are short-day, seasonal breeders regulated by photoperiodic cycles. The primary physiological change that occurs in bucks before the breeding season involves an increase in testis size 1 This manuscript includes research supported and conducted by the Texas Agric. Exp. Stn., The Texas A&M Univ. System. This study was a contribution to the Western Regional Research Project W-112, Reproductive Performance in Domestic Ruminants.
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bucks compared with control and MGA-treated bucks. Melengestrol acetate-treated bucks had a maximum sperm concentration in the ejaculate that was three times (P < 0.05) that of control bucks and nine times (P < 0.05) that of zeranol-treated bucks. Antler weight was the least (P < 0.01) for bucks receiving zeranol and greatest (P < 0.10) for MGA-treated bucks; intermediate values were recorded for the control bucks. Aggressive behavior was delayed (P < 0.05) for zeranol-treated bucks until treatment effects were overcome. Melengestrol acetate-treated bucks had decreased (P < 0.01) aggressive behavior compared with control bucks. Melengestrol acetate-treated bucks had increased (P < 0.05) serum testosterone concentrations compared with control and zeranol-treated bucks. Human chorionic gonadotropin-stimulated peak serum testosterone concentrations for zeranol-treated bucks were delayed (P < 0.01) compared with control and MGA-treated bucks. Although zeranol-treated bucks overcame treatment effects, they were never able to reach testicular measurements or sperm concentrations equal to those of the control or MGA-treated bucks. Zeranol and MGA treatments may have both positive and negative effects that can be utilized when producing slaughter bucks.
and an increase in testosterone secretion that lead to increased spermatogenesis (Asher et al., 1987; Johnson and Everitt, 1995) . Increased secretion of testosterone results in increased aggression (Johnson and Everitt, 1995) . Peak demand for venison is in the fall and winter months, which coincides with the onset of the breeding season and increased aggression.
This behavior involves head butting, bruising, loss of gain due to fighting, and sometimes death. In the beef and swine industry, castration is the traditional method for controlling aggression. Castration is not a useful alternative with fallow deer. Without the increase in testosterone the animals have increased fat deposition and greatly reduced growth rates, which results in lower carcass weights and reduced muscle mass in the more highly valued cuts of meat (Hogg et al., 1990) . Methods of controlling aggression have not been devel-oped for intact fallow bucks. Current research with zeranol, a resorcylic acid lactone discovered by Stob et al. (1962) , using fallow bucks has shown that it may reduce aggressive behavior for a limited time, but as bucks increase in age the effects of zeranol are attenuated (Webb et al., 1999) . Melengestrol acetate (MGA), an orally active synthetic progestin, is used to promote growth, improve feed efficiency, and control estrus in feedlot heifers (Lauderdale et al., 1977; Lauderdale, 1983) . Progestins have been shown to inhibit the aggressive effects of androgens (Gravance et al., 1996) . The objective of this trial was to determine whether zeranol or melengestrol acetate can reduce aggressive behavior during the seasonal rut and reduce antler growth, testes growth, and sexual activity without affecting ADG or BW.
Materials and Methods
From May 20, 1999, through January 4, 2000, 15 yearling fallow bucks were housed at the Texas Agricultural Experiment Station in Overton, TX. Bucks were randomly assigned by BW into one of three treatments: 1) control (n = 5), 2) zeranol (36 mg; Schering-Plough Animal Health Corp., Union, NJ) (n = 5), or 3) melengestrol acetate (100 gؒanimal ; Pharmacia & Upjohn Company, Kalamazoo, MI) (n = 5). The Texas A&M University Institutional Animal Care and Use Committee approved (LA-499-2) the experimental protocol defined within this section. Each group was maintained in 0.2024-ha plots of ryegrass/Coastal bermudagrass pasture and had ad libitum access to water. They were fed a 3:1 corn/soybean meal concentrate at 0.45 kgؒani-mal
. Mineral supplementation was included with the concentrate. Due to drought conditions additional supplementation of alfalfa pellets was supplied at 0.90 kgؒanimal −1 ؒd −1 from September 1, 1999, through January 4, 2000.
Zeranol-treated bucks received 36 mg of zeranol (applied in the ear with a standard Ralgro gun; IMC Chemical Group, Terre Haute, IN) at d 0 (May 20) and were reimplanted at 90-d intervals (Godfrey et al., 1989) . Melengestrol acetate treatment was included in the concentrate at 100 gؒanimal
. This treatment amount was determined by taking the standard cattle dose (0.3 to 0.5 mgؒanimal
) and reducing it according to the approximate BW of bulls to that of bucks. To provide the MGA treatment, corn meal (100 g) was combined with MGA (10 mg) and mixed for 10 min. This mixture was then combined with 11.34 kg of soybean meal in a V-Mixer (General Machine Co., Newark, NJ) for 2 h. Subsequently, 34.02 kg of corn was added and mixed for an additional 2 h. This ration was then bagged and stored under secure conditions. Body weights were recorded at 2-wk intervals, yielding ADG and total gains to determine treatment effects on body growth. Body condition scores (1 [thin] to 9 [obese]) (Willard, 1996) , testis circumference, length, width, and depth were measured at 2-wk intervals. ) and compared between groups (Lunstra et al., 1988; Godfrey et al., 1990) . Antler growth and development was evaluated every 2 wk, and as each group developed hard antlers they were removed (zeranoltreated, July 15; control, July 29; MGA, August 25, 1999) using an obstetrical saw-wire blade with handles and weighed. Antlers were determined to be hard when bucks began to rub and remove velvet.
Plain (uncoated) 16-× 125-mm evacuated blood collection tubes with a maximum volume of 15 mL were used to obtain blood samples via the jugular vein at 2-wk intervals. Samples were centrifuged at 1,900 × g for 30 min at 4°C, and serum was harvested and stored at −20°C until samples were analyzed. Testosterone concentrations were determined using a specific RIA (Vera-Avila et al., 1997) . The testosterone antibody (#250 anti-testosterone-11-BSA; G. D. Niswender, Ft. Collins, CO) was diluted with PBS + 0.1% gelatin to a working dilution of 1:50,000. The average testosterone detection limit was 0.01 ng/mL. Extraction recovery averaged 86% and inter-and intra-assay coefficients of variation were 13.4 and 12.5%, respectively.
When the first control buck began to rub velvet off its antlers, an hCG challenge (250 IU; Solvay Animal Health, Mendota Heights, MN; M. S. Amoss, personal communication) was applied by i.v. injection to each buck in all groups to evaluate testosterone secretion (Wise, 1992) . Immediately after the first jugular blood sample was collected, hCG was injected and five subsequent hourly samples were taken thereafter. These samples were handled in the same manner as samples take at 2-wk intervals. The hCG challenge was repeated at 28-d intervals. Ejaculates were collected by electroejaculation (Asher et al., 1987) when the first control buck began to rub its velvet off, and every 2 wk thereafter, to determine concentration, motility, progressive motility, and morphology of sperm. Aggressive behavior was evaluated within each group when hard antlers were removed and at 28-d intervals; scores were assigned to head bunts, head pushes, body blows, and avoidance (Webb et al., 1999) . Head bunts involved two individuals hitting and then releasing, and head pushes involved consistent pushing. Body blows were evaluated when a buck delivered a blow to another anywhere except the head region. Usually after a buck had been hit, it either reacted with a return body blow or avoided confrontation and received an avoidance score. Total aggression was calculated by adding the head bunts, head pushes, and body blows.
The total number of animals used in this trial changed due to uncontrollable circumstances. When deer are injured, dominance within the pen is re-established. Even if the injury is minor, an animal will be shunned and challenged. Throughout this trial a total of three animals (one from each treatment) were removed from their groups due to injury or death. Two bucks (one MGA-and one zeranol-treated buck) were removed due to leg injuries occurring while in the chute, and one control buck was killed on d 168.
Body (BW and mean body condition score) and testis (right and left testis length, width, and depth) growth traits and aggression (head pushes, head bunts, body blows, avoidance, total aggression and head pushes + head bunts) and testosterone secretion profiles were analyzed using GLM procedures specific for repeated measures (SAS Inst. Inc., Cary, NC). Antler length and weight; day of first, maximum, and total sperm concentration; average daily gain and total gain; maximum and mean aggression; and maximum scrotal circumference, paired testis volume data, and testosterone secretion parameters were analyzed using GLM procedures of SAS.
Results

Body Measurements
Body weight was influenced by day (P < 0.01) and a treatment × day interaction (P < 0.01). Zeranol-treated bucks failed to increase in BW from mid-August through early January, whereas control and MGAtreated bucks increased (P < 0.05 and < 0.10, respectively) in BW through mid-November (Figure 1 ). During this time frame, all bucks were undergoing the seasonal rut. Average daily gain was greater (P < 0.02) in controls (48.6 ± 4.0 g) than in zeranol-treated (31.8 ± 4.0 g) bucks, and MGA-treated bucks were intermediate (42.6 ± 4.0 g). Body condition scores decreased throughout the experiment in all treatment groups in a similar fashion (Figure 2 ).
Antler development was influenced (P < 0.05) by treatment. Control and MGA-treated bucks tended to have heavier antlers (P < 0.08) than the zeranol-treated bucks (Table 1) . Antler weight for MGA-treated bucks was nearly double that of the control bucks (P < 0.10). A tendency was observed for antlers from MGA-treated bucks to be longer (P < 0.10) than those of the zeranoltreated bucks (Table 1) .
Scrotal circumference was affected by treatment (P < 0.01), day (P < 0.01), and a treatment × day interaction (P < 0.01) (Figure 3 ). Control and MGA-treated bucks had similar scrotal circumference measurements throughout the trial. Zeranol-treated bucks had a delay (P < 0.05) in the seasonal increase in scrotal circumference that peaked in November; MGA-treated bucks peaked in September and controls in early October (Figure 3 ). Zeranol-treated bucks never reached as large a scrotal circumference as the control and MGA-treated bucks. Maximum scrotal circumference occurred later (P < 0.01) in the zeranol-treated bucks than in the con- trol and MGA-treated bucks (Table 1) . When zeranoltreated bucks peaked in scrotal circumference, control and MGA-treated bucks had begun their seasonal decline.
Paired testes volume was affected by treatment (P < 0.01), day (P < 0.01), and a treatment × day interaction (P < 0.01) (Figure 4) . Day of maximum paired testes volume for zeranol-treated bucks was later (P < 0.01) compared with control and MGA-treated bucks (Table  1) . Zeranol-treated bucks failed to reach maximum paired testes volume measurements similar to those of the control and MGA-treated bucks. 
Semen Evaluation
Zeranol-treated bucks had a tendency to be delayed (P < 0.10) in having first sperm detected in the ejaculate and were 30 to 42 d later compared with control and MGA-treated bucks (Table 2) . Body weight and body condition score at first sperm did not differ among treatments. Right and left testicle length, width, and depth (P < 0.05) were smaller for zeranol-treated bucks relative to the control group. As a result of these measurements, zeranol-treated bucks were smaller in scrotal circumference (P < 0.01) and paired testes volume (P < 0.01) on day of first sperm in the ejaculate compared with control and MGA-treated bucks ( Table 2) .
Day of maximum sperm in the ejaculate was not affected by treatment (P > 0.10) ( Table 2 ). Treatment did not affect BW, body condition score, scrotal circumference, or paired testes volume on day of maximum sperm production (P > 0.10). Right and left testis lengths were reduced for zeranol-treated bucks (P < 0.10 and < 0.05; respectively) compared with control and MGA-treated bucks. All other testicular measurements at maximum sperm in the ejaculate were unaffected by treatment. Melengestrol acetate-treated bucks had sperm numbers in the ejaculate 3.5 times greater (P < 0.05) than those in ejaculate of the control bucks. Maximum total sperm numbers for MGA-treated bucks were nine times (P < 0.05) greater than those for zeranol-treated bucks. Zeranol-treated bucks tended to have decreased (P < 0.10) percentage motility compared with the control bucks. Percentage abnormal and percentage motility in zeranol-treated bucks were similar to those of control and MGA-treated bucks.
Testosterone
Serum testosterone concentrations were affected by treatment (P < 0.01) ( Figure 5 ). Melengestrol acetatetreated bucks had increased serum testosterone concentrations compared with control and zeranol-treated bucks from d 28 through 210 ( Figure 5 ). Basal testosterone concentrations were affected by a day (P < 0.01) and a treatment × day interaction (P < 0.02) ( Table 3) . There was a treatment (P < 0.06), day (P < 0.001), and a treatment × day interaction (P < 0.02) affecting hCGstimulated peak testosterone concentrations (Table 3) . Zeranol-treated bucks maintained lower (P < 0.01) hCGstimulated peak testosterone concentrations than control and MGA-treated bucks through mid-September (Table 3) .
Zeranol-treated bucks had reduced (P < 0.01) hCGstimulated testosterone peak amplitude compared with control bucks (Table 3) . By mid-October, zeranoltreated bucks had overcome the testicular suppression and had increased testosterone concentrations. Maximum peak amplitude did not differ among treatments, but zeranol-treated bucks were delayed (P < 0.05) in reaching the maximum in testosterone response compared with control and MGA-treated bucks (Figure 6 ). Within a row, within a measurement day, means with different superscripts differ (P < 0.10).
c,d
Within a row, within a measurement day, means with different superscripts differ (P < 0.05).
No differences were detected among (P > 0.10) treatments in the timing of each hCG-stimulated testosterone peak (Table 3) . Area under the hCG-induced serum testosterone curve was influenced by day (P < 0.01) effect and a treatment × day interaction (P < 0.01) (Figure 7 ). Testosterone response to hCG increased until mid-September for control and MGA-treated bucks. After this time, both control and MGA-treated bucks began to decrease in response to hCG. Zeranol-treated bucks maintained reduced testosterone response to hCG through mid-September. Testosterone response to hCG increased in zeranol-treated bucks by mid-October, when it reached its maximum. Maximum area under the hCG response curve was not different (P > 0.10) for the control bucks compared with the zeranol-and MGA-treated bucks (Figure 7) . However, hCG-stimulated testosterone responses in zeranol-treated bucks were reduced (P < 0.10) compared with those in MGA-treated bucks. The day of maximum area under the curve for zeranol- (Pooled SEM = 0.86; day P < 0.01; treatment × day P < 0.02).
b (Pooled SEM = 3.17; treatment P < 0.06; day P < 0.001; treatment × day P < 0.02). 
Aggressive Behavior
Body blows did not differ (P > 0.10) among treatments. There was a treatment (P < 0.10), day (P < 0.10), and a treatment × day interaction (P < 0.01) affecting avoidance (Table 4) . Zeranol-and MGA-treated bucks had decreased avoidance during the August and September observations. This pattern tended to change during October, when zeranol-treated bucks had increased avoidance whereas control and MGA-treated bucks remained lower (P < 0.10 and < 0.10; respectively). Avoidance was similar (P > 0.10) among treatments for November but returned to the previous pattern, with zeranol-treated bucks having increased avoidance during the December observation. All treatments were similar (P > 0.10) on January 4.
There was a treatment (P < 0.01), day (P < 0.10), and a treatment × day interaction (P < 0.01) influencing Pooled SEM = 3.01; treatment P < 0.10; day P < 0.10; treatment × day P < 0.01.
Means in a row with different superscripts differ (P < 0.10).
d,e
Means in a row with different superscripts differ (P < 0.05). Pooled SEM = 1.12; treatment P < 0.01; day P < 0.10; treatment × day P < 0.01.
Means in a row with different superscripts differ (P < 0.05).
d,e Means in a row with different superscripts differ (P < 0.10).
head pushes (Table 5) . Control bucks had a greater occurrence of head pushes compared with zeranol-and MGA-treated bucks early and late in this trial. By October 13, zeranol-treated bucks tended to have increased (P < 0.10) numbers of head pushes compared with control and MGA-treated bucks. Melengestrol acetatetreated bucks had fewer head pushes than controls throughout the trial except on October 13.
Head bunts were affected by a day (P < 0.01) and a treatment × day interaction (P < 0.10; Table 6 ). Melengestrol acetate-treated bucks had zero occurrence of head bunts until January 4 and were lower (P < 0.05) than control or zeranol-treated bucks on September 15.
Total aggression was calculated by combining body blows, head pushes, and head bunts and was affected by a treatment × day interaction (P < 0.05). Total aggression was highest in control bucks during the early rut (August 17 through September 15) but total aggression was high in the zeranol-treated bucks on October 13 and December 8 (Table 7) . Melengestrol acetate-treated bucks had the lowest total aggression on most sampling days.
Head pushes and head bunts were combined to evaluate total head aggression. A combined relationship between pushes and bunts demonstrates active aggressive behavior between both bucks involved. There was a treatment (P < 0.05), day (P < 0.05), and a treatment × day interaction (P < 0.01) affecting total head aggression (Table 8) . Zeranol-and MGA-treated bucks had reduced Means in a row with different superscripts differ (P < 0.10). Means in a row with different superscripts differ (P < 0.05).
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total head aggression for much of the evaluation period compared with the control bucks. However, by October 13, zeranol-treated bucks tended to have greater head aggression than the control (P < 0.10) and MGA-treated (P < 0.10) bucks. Throughout the observation period, MGA-treated bucks recorded low levels of head aggression compared with the control and zeranol-treated bucks. Adding the scores for each behavior area and taking the average determined average aggression scores. Treatments were not different (P > 0.10) for average body blows or total aggression (Table 9) . Zeranoland MGA-treated bucks tended to have lower (P < 0.10) average occurrences of head pushes and head aggression than control bucks. Melengestrol acetate-treated bucks tended to have reduced (P < 0.10) average head bunts compared with control bucks. Maximum aggression scores were determined by taking the maximum number for each behavior area for each animal. No treatment differences (P > 0.10) were observed for maximum body blows or total aggression (Table 9) . Maximum avoidance tended to be lower (P < 0.10) for MGA-treated bucks than for control and zeranol-treated bucks. Zeranol-and MGA-treated bucks had lower (P < 0.05) maximum occurrences of head pushes and head pushes plus head bunts than control bucks. Maximum head bunts were reduced for MGA-treated bucks compared with control (P < 0.05) and zeranoltreated (P < 0.10) bucks.
Discussion
Fallow bucks in this experiment followed the expected trend with increased BW during the spring and summer months and decreased BW during the rut (Asher, 1985; Asher et al., 1987) . Control and MGA-treated bucks had increased (P < 0.05 and < 0.10, respectively) BW gains compared with zeranol-treated bucks. Each treatment group maintained BW after the onset of the rut through the end of the trial. Bucks were on a positive plane of nutrition for the duration of this trial, and variation of weights to other bucks must be attributed to treatment or genetic makeup. Body condition is expected to be greater during the summer months and then decrease with rutting activity (Blaxter et al., 1974) . Body condition scores decreased throughout the experiment from 6.5 to 5.5. Following the early rut behavior from late October until January, all bucks maintained body condition.
Antlerogenesis begins in the early spring when testosterone concentrations are at their lowest (Lincoln, 1971) . Antler development is closely correlated to seasonal photoperiodic cycles (Suttie and Fennessy, 1992) . As serum testosterone concentrations increase in the summer, antlers begin to harden (Lincoln, 1971) . Zeranol-treated bucks had reduced antler development compared with control (P < 0.05) and MGA-treated (P < 0.01) bucks. These data demonstrate that MGA can increase and zeranol can decrease antler development as measured by antler length and weight. Current research by Barrell et al. (1999) has determined the presence of estrogen receptors in the fibrous tissues surrounding antlers of red deer. Because zeranol is an estrogen-like compound, it is possible that zeranol functioned in the same manner as estrogen to bind these receptors and result in reduced antler growth. The hCG-stimulated peak serum testosterone concentration was delayed (P < 0.01) for zeranoltreated bucks. Zeranol-treated bucks developed antlers while having lower serum testosterone concentrations than control and MGA-treated bucks. Antler development increased in MGA-treated bucks compared with control and zeranol-treated bucks. Melengestrol acetatetreated bucks had antler weights nearly double that of control bucks (P < 0.10). Melengestrol acetate-treated bucks had increased serum testosterone concentrations during antler development compared with control (P < 0.01) and zeranol-treated (P < 0.001) bucks. The increased serum testosterone concentrations seen in this study probably do not explain the increase in antler growth in the MGA-treated bucks. Means in a row with different superscripts differ (P < 0.04).
Means in a row with different superscripts differ (P < 0.06)
Means in a row with different superscripts differ (P < 0.09).
Because fallow bucks are seasonal breeders, testicular dimension changes depending on season. Testicular size increases with onset of the summer solstice, resulting in increased spermatogenesis (Lincoln, 1971) . Testis weights for bucks treated with zeranol (12 mg at 90-d re-implant intervals) have been reported to be half that of untreated bucks (Wilson et al., 1998) . Zeranol-treated bucks were delayed in development of scrotal circumference (P < 0.05) and paired testes volume (P < 0.06) compared with control and MGA-treated bucks. In a sense, bucks undergo pubertal-like changes every year. Because zeranol-treated bucks were delayed in testicular development, spermatogenesis might be expected to also be delayed. Amman (1983) reported that bulls with large testes produced more sperm than bulls with small testes.
Zeranol-treated bucks were able to overcome treatment effects and ultimately increased in scrotal circumference and serum testosterone concentrations similar to reports in bulls treated with zeranol (Juniewicz et al., 1985; Staigmiller et al., 1985; Godfrey et al., 1989) . A tendency was observed for day of first sperm to be delayed (P < 0.10) for zeranol-treated bucks by nearly 30 d relative to control and MGA-treated bucks. When zeranol-treated bucks began to increase in testis size and testosterone concentrations, spermatogenesis increased, resulting in elevated sperm production. Although zeranol-treated bucks increased in spermatogenesis, they never achieved the same number of sperm in the ejaculate that was found in control and MGA-treated bucks. Suppressed spermatogenesis in bucks or bulls treated with zeranol is not surprising due to reduced testosterone concentrations (Juniewicz et al., 1985; Silcox et al., 1986) . Melengestrol acetate-treated bucks were similar to control bucks for day of first sperm. Day of maximum sperm in the ejaculate was similar between all treatments. Melengestrol acetate-treated bucks had 3.5 times the number of maximum sperm in the ejaculate compared with control bucks (P < 0.05) and nine times more than zeranol-treated bucks (P < 0.05). Past research with the use of MGA in similar trials reported decreased androgen concentration (Chinese goral; Patton et al., 2000) and decreased spermatogenesis (Muntjack; Stover et al., 1987) . Melengestrol acetate is approved by the FDA for use in cattle at 0.3 to 0.5 mgؒanimal
. Both of these experiments used large dose amounts (0.3 to 1 mg/d; Stover et al., 1987 and 1.54 mg/kg; Patton et al., 2000) . In the present study, dosage was determined by taking FDA-approved cattle dose amounts and adjusting them to the BW of fallow bucks, thereby resulting in a dose of 100 gؒanimal
. With this dose, serum testosterone concentrations, antlerogenesis, and spermatogenesis were increased.
Zeranol-treated bucks exhibited delayed aggression, but as testosterone concentrations increased they overcame this delay and aggressive behavior returned to normal later in the breeding season. Compared with control bucks, zeranol-and MGA-treated bucks had fewer (P < 0.05 and < 0.05; respectively) occurrences of avoidance and, as time progressed, zeranol-treated bucks began to increase in avoidance whereas MGA-treated bucks continued unchanged throughout the remainder of this trial. Ultimately, zeranol-treated bucks were delayed in aggressive behavior until bucks overcame treatment effects and aggression gradually increased. This confirms research previously reported by Webb et al. (1999) that zeranol suppresses early aggression in yearling fallow bucks. Head aggression displays violent aggressive behavior between both bucks involved. Zeranol-treated bucks had reduced head pushes until mid-October, when treatment effects were overcome and the occurrence of head pushes increased (P < 0.10) above control and MGAtreated bucks. Melengestrol acetate-treated bucks had fewer occurrences of head pushes, head bunts, and maximum head bunts compared to control and zeranoltreated bucks. Melengestrol acetate-treated bucks did not participate in head bunt activity until the end of this trial. Zeranol-and MGA-treated bucks had fewer (P < 0.10) average head pushes and head aggression than control bucks.
Overall, zeranol-and MGA-treated bucks had reduced head aggression compared with control bucks and MGAtreated bucks had less aggression compared with zeranol-treated bucks. Melengestrol acetate-treated bucks had increased testosterone concentrations, so it would be expected that aggressive behavior would be enhanced. However, MGA-treated bucks had decreased aggressive behavior. This is consistent with research involving the use of progestins in reducing aggression in several species such as the muntjac (Stover et al., 1987) , hamster (Fraile et al., 1987) , mouse (Soares et al.,1977; Gravance et al., 1996) , scimitar horned oryx (Blumer et al., 1992) , and fringe-eared oryx (Patton et al., 2001) . Although past research agreed that the use of progestins could reduce aggressive behavior, this trial disagrees with the serum testosterone concentrations that have been reported. Research that reported steroid concentrations indicated a decline in testosterone concentrations, whereas the current project reports an increase. It is uncertain why MGA-treated bucks had decreased aggressive behavior while testosterone concentrations were increased. It is possible that testosterone metabolites were influenced to cause decreased aggression in MGA-treated bucks. The relationship between the synthesis of 5α-dihydrotestosterone and testosterone may be unbalanced, causing less aggression. Further study of MGA is needed to determine how this mechanism functions. Although some aggression is evident in MGA-treated bucks, it is dramatically decreased relative to untreated males.
Implications
If bucks are slaughtered while aggressive behavior is reduced through administration of zeranol or melengestrol acetate, producers could increase profits due to fewer bruised carcasses and fewer injury-related deaths in the herd. Unfortunately, peak harvest slaughter dates for venison in the United States are late in the year, by which time aggressive behavior for zeranol-treated bucks had returned to normal in the current study. Further testing of zeranol and melengestrol acetate may eventually yield a protocol that will further help producers maximize profits from venison production regardless of slaughter dates. Venison production is hormone-free, and consumers and producers will be reluctant to use or purchase products from treated animals. This trial is one step in the process of determining efficient means by which we may increase venison production by decreasing aggressive behavior.
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